Skip to content
  • EN
  • About
    • About GFAN
    • GFAN Regional Partners
    • GFAN Strategy 2026-2030
  • News
    • GFAN Guide to Global Fund Board Meetings – June 2026
    • Report To Membership 2025
  • Tools for Advocacy
    • Grant Cycle 8
      • Key Resources for Grant Cycle 8
      • GFAN Brief – Stop the Slide on the Set-Asides
      • GFAN Brief – Guide for advocates on how Global Fund Grants can speed up and expand access to innovations
      • Transformative Impact of the Global Fund
      • Why Advocate for Debt to Health?
    • US Health MoUs
      • GFAN’s Helpful U.S. MoU Reading Guide!
      • US Bilateral MoUs for Health and Global Fund’s GC8: A Primer for Advocates
      • Key Partner Resources for US Health MoUs
    • Reframing Solidarity : Tackling Anti-ODA Narratives
  • GFAN Publications
    • All publications
    • Global Fund 54th Board Meeting – GFAN Report
    • Health In A Fractured Aid Landscape
  • Blog
  • GFAN Calls
    • 2026 GFAN Calls
    • 2025 GFAN Calls
    • 2024 GFAN Calls
    • 2023 GFAN Calls
    • 2022 GFAN Calls
    • 2021 GFAN Calls
    • 2020 GFAN Calls
    • 2019 GFAN Calls
  • Speakers
    • GFAN Speakers Bureau
    • Tool Kit
    • Photo and Video User Guide
  • Contact
  • Archived
    • 8th Replenishment
      • Pledge Tracker & Replenishment Advocacy Tools
      • 8th Replenishment Issue Briefs
      • Here I Am 2.0
      • Investment Case Advocacy Toolkit
      • How to Close a Funding Gap?
      • What Civil Society Expects from the 8th Replenishment
    • Global Fund Reprogramming Resources
    • GFAN @ World Health Summit 2025
    • GC7 Resources
    • Resources on the Pandemic Fund
    • COVID-19 Resources
    • TB HLM 2023 Affected Communities and Civil Society Coordination Hub
    • 7th Replenishment
      • Still Waiting, Still Dying: KVP Brief
      • GFAN Pledge Tracker
      • Fully Fund the Global Fund – Report and Briefs
        • Fully Fund the Global Fund: Get Back on Track to End AIDS, TB and Malaria in a Covid World
        • Fully Fund the Global Fund: Issue Briefs
        • Fully Fund the Global Fund: Social Media Kit
      • Pledging Conference 2022 @NYC
      • Preparatory Meeting & IC Advocacy Toolkit
        • 7 Asks for the 7th Replenishment
        • CS Statement on the Investment Case
    • GFAN in Munich @AIDS24
    • GFAN in Montréal @AIDS22
    • Global Fund Strategy Development
      • Global Fund Strategy Toolkit
      • Summary of top-level priorities areas for civil society & communities
Global Fund Advocates Network
  • Twitter
  • Facebook
  • YouTube

JOIN GFAN

Gene Drive and Mosquitoes: Turning a Deadly Foe Into an Ally

Jun 2025

June 15, 2025
Blog / malaria

Krystal Birungi 

Entomologist and Malaria Advocate, Target Malaria I GFAN Speaker

 

Malaria remains a daily threat across Africa. In 2023 alone, the continent accounted for 95% of the world’s 597,000 malaria-related deaths. The most vulnerable are our children and pregnant women. Every minute, a child in Africa dies from this disease.

But malaria doesn’t just rob us of lives, it also drains our economies. Across Africa, the disease costs us an estimated $12 billion each year. In Uganda, my home country, we lose more than $500 million per decade. During peak seasons, malaria can cause up to half of all outpatient visits and nearly a fifth of hospital admissions.

Photo Credit: Target Malaria

Worse still, the challenges are growing. Climate change, resistance to insecticides, and reduced effectiveness of antimalarial drugs are threatening the progress we’ve made. So, we’re left with a difficult question: Must we accept malaria as an inevitable part of life?

I don’t believe we should. And as both a scientist and a mother, I believe we can do more.

At Target Malaria, the nonprofit research consortium I work with, we’re exploring a new frontier in the fight against malaria: gene drive technology.

Here’s how it works: We introduce a genetic trait into the Anopheles mosquito, one of the main carriers of the malaria parasite. This gene is passed down to offspring at a higher-than-normal rate, gradually reducing the population’s ability to reproduce. Over time, the mosquito population declines — potentially enough to interrupt malaria transmission altogether.

By targeting genes involved in the ability of mosquitoes to mate, lay eggs or reproduce, gene drives affect their reproduction and reduce their population. Target Malaria.

A large-scale modeling study across 13 West African countries showed that gene drive mosquitoes could reduce populations of malaria-transmitting species by 71% to 98%. When combined with existing tools like vaccines and new-generation mosquito nets, it could prevent up to 60% more clinical malaria cases.

This technology is not designed to eradicate all mosquitoes — nor could it. Of more than 3,500 known mosquito species, only about 30 are a public health concern. Of those, just three are responsible for most malaria transmission in Africa. Our work is focused on this narrow target.

Genetic approaches also offer some clear advantages for Africa’s unique health landscape. They require less day-to-day management than current interventions, making them particularly suited for rural and hard-to-reach communities. And because they are species-specific, they offer a more environmentally targeted solution. But we are taking a cautious, transparent approach. We’re still years away from releasing gene drive mosquitoes into the wild — and we won’t take that step without the required regulatory approvals and the agreement of the communities involved.

In the meantime, we are conducting rigorous ecological studies to ensure that reducing one mosquito species won’t cause ripple effects in the environment. Early results of ecological studies conducted on the Anopheles mosquitoes in Ghana are promising. Animals, like birds and bats, that prey on these mosquitoes appear to have a varied diet and thus would be able to survive without them.

We’re also listening to community members, civil society groups, and environmental advocates have voiced concerns because science must serve people, not just data.

Malaria isn’t just a scientific challenge — it’s personal. I have lost people I love to this disease. I have watched it strike hardest in communities that already face poverty, limited health access, and climate vulnerability. Science gives us the tools to change the future.

Gene drive won’t be a silver bullet. But as part of an integrated approach alongside existing tools and partnerships, it could help turn one of our oldest enemies into an unlikely ally.

This isn’t science fiction. It’s science — African-led, community-centered, and driven by hope.

And that’s a future worth fighting for.

This blog was originally published on Semafor.com

Recent Posts

  • GFAN Brief – Guide for advocates on how Global Fund Grants can speed up and expand access to innovations
  • GFAN Brief – Stop the Slide on the Set-Asides
  • GLOBAL FUND 55TH BOARD MEETING – GFAN REPORT
  • GFANers Guide to AIDS 2026: Updates and Information
  • GFAN Guide to Global Fund Board Meetings – June 2026

GFAN Publications

  • GFAN Brief – Guide for advocates on how Global Fund Grants can speed up and expand access to innovations

  • GFAN Brief – Stop the Slide on the Set-Asides

  • GLOBAL FUND 55TH BOARD MEETING – GFAN REPORT

  • GFAN Guide to Global Fund Board Meetings – June 2026

  • GFAN SPEAKERS BUREAU 2026-2030

  • News
  • Blog
  • Speakers Bureau
  • Calls
  • GFAN Publications
  • About
JOIN GFAN
Global Fund Advocates Network
  • Twitter
  • Facebook
  • YouTube

Global Fund Advocates Network 2026